Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs

Chronic lymphocytic leukemia (CLL), characterized by the accumulation of mature B lymphocytes in the blood, bone marrow and lymphoid tissues, is the most common adult leukemia in Western countries. The treatment landscape for CLL has evolved dramatically over the past decade with the introduction of targeted therapies, particularly Bruton's tyrosine kinase inhibitors and B-cell lymphoma 2 inhibitors. Despite the efficacy of these agents, a growing population of patients develop resistance to both classes of drugs, resulting in double refractory disease. This review explores the current understanding of double refractory CLL and examines emerging therapeutic approaches. We discuss novel agents including noncovalent BTK inhibitors, BTK degraders, bispecific antibodies, chimeric antigen receptor T-cell therapies, and innovative combination strategies. Additionally, we provide a comprehensive analysis of current clinical trials evaluating these novel approaches. Noncovalent BTK inhibitors, particularly pirtobrutinib, has shown impressive activity in patients who have progressed on covalent BTKi. Bispecific antibodies and chimeric antigen receptor T-cell therapies harness the power of the immune system to target CLL cells, achieving high response rates and durable remissions in heavily pretreated patients. The FDA approval of lisocabtagene maraleucel represents a significant milestone in the treatment of double refractory CLL, providing a potentially curative option for eligible patients. The development of effective treatments for double refractory CLL represents an urgent unmet clinical need and the promising results from emerging therapies offer hope for improved outcomes in this challenging patient population.